Adenosine A2A Receptor Deficiency Up-Regulates Cystatin F Expression in White Matter Lesions Induced by Chronic Cerebral Hypoperfusion

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Duan, Wei ^a   Ran, Hong ^a   Zhou, Zhujuan ^a   He, Qifen ^a   Zheng, Jian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; CYSTATIN; CYSTATIN F; CYSTEINE PROTEINASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN PERFUSION; CORPUS CALLOSUM; DEMYELINATION; DISEASE EXACERBATION; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; MALE; MOLECULAR MECHANICS; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; WHITE MATTER LESION; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CEREBROVASCULAR CIRCULATION; CEREBRUM; CORPUS CALLOSUM; CYSTATINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ADENOSINE A2A; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

MUS;

EID: 84871436270     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052566     Document Type: Article

References (42)

1. Moorhouse P, Rockwood K, (2008) Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 7: 246-255.
2. Wakita H, Tomimoto H, Akiguchi I, Lin JX, Miyamoto K, et al. (1999) A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia. Neuroreport 10: 1461-1465.
3. Deng Y, Lu J, Sivakumar V, Ling EA, Kaur C, (2008) Amoeboid microglia in the periventricular white matter induce oligodendrocyte damage through expression of proinflammatory cytokines via MAP kinase signaling pathway in hypoxic neonatal rats. Brain Pathol 18: 387-400.
4. Farkas E, Donka G, de Vos RA, Mihaly A, Bari F, et al. (2004) Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol 108: 57-64.
5. Gehrmann J, Matsumoto Y, Kreutzberg GW, (1995) Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20: 269-287.
6. Kraft AD, Harry GJ, (2011) Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8: 2980-3018.
7. Ma J, Tanaka KF, Shimizu T, Bernard CC, Kakita A, et al. (2011) Microglial cystatin F expression is a sensitive indicator for ongoing demyelination with concurrent remyelination. J Neurosci Res 89: 639-649.
8. Izzotti A, Pulliero A, Orcesi S, Cartiglia C, Longobardi MG, et al. (2009) Interferon-related transcriptome alterations in the cerebrospinal fluid cells of Aicardi-Goutieres patients. Brain Pathol 19: 650-660.
9. Turk V, Stoka V, Turk D, (2008) Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 13: 5406-5420.
10. Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N, et al. (2000) Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood 96: 2206-2214.
11. Obata-Onai A, Hashimoto S, Onai N, Kurachi M, Nagai S, et al. (2002) Comprehensive gene expression analysis of human NK cells and CD8(+) T lymphocytes. Int Immunol 14: 1085-1098.
12. Hamilton G, Colbert JD, Schuettelkopf AW, Watts C, (2008) Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J 27: 499-508.
13. Mayne M, Fotheringham J, Yan HJ, Power C, Del Bigio MR, et al. (2001) Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49: 727-735.
14. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, et al. (2003) Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112: 883-891.
15. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, et al. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657-682.
16. Duan W, Gui L, Zhou Z, Liu Y, Tian H, et al. (2009) Adenosine A2A receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice. J Neurol Sci 285: 39-45.
17. Omori K, Naruishi K, Yamaguchi T, Li SA, Yamaguchi-Morimoto M, et al. (2007) cAMP-response element binding protein (CREB) regulates cyclosporine-A-mediated down-regulation of cathepsin B and L synthesis. Cell Tissue Res 330: 75-82.
18. Itziou A, Dimitriadis VK, (2009) The potential role of cAMP as a pollution biomarker of terrestrial environments using the land snail Eobania vermiculata: correlation with lysosomal membrane stability. Chemosphere 76: 1315-1322.
19. Colbert JD, Plechanovova A, Watts C, (2009) Glycosylation directs targeting and activation of cystatin f from intracellular and extracellular sources. Traffic 10: 425-437.
20. Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, et al. (2004) Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 10: 1081-1087.
21. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, et al. (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200.
22. Shibata M, Ohtani R, Ihara M, Tomimoto H, (2004) White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35: 2598-2603.
23. Orru M, Quiroz C, Guitart X, Ferre S, (2011) Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology 61: 967-974.
24. Monopoli A, Casati C, Lozza G, Forlani A, Ongini E, (1998) Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther 285: 9-15.
25. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22: 1967-1975.
26. Pintor A, Quarta D, Pezzola A, Reggio R, Popoli P, (2001) SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur J Pharmacol 421: 177-180.
27. Hof PR YW, Bloom FE, Belichenko PV, Celio MR. (2000) Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/SV Mouse brain. Amsterdam: Elsevier Science.
28. Heid CA, Stevens J, Livak KJ, Williams PM, (1996) Real time quantitative PCR. Genome Res 6: 986-994.
29. Ramakers C, Ruijter JM, Deprez RH, Moorman AF, (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62-66.
30. Bangert C, Friedl J, Stary G, Stingl G, Kopp T, (2003) Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J Invest Dermatol 121: 1409-1418.
31. Kopitar-Jerala N, (2006) The role of cystatins in cells of the immune system. FEBS Lett 580: 6295-6301.
32. Lehnardt S, (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58: 253-263.
33. Sriram S, (2011) Role of glial cells in innate immunity and their role in CNS demyelination. J Neuroimmunol 239: 13-20.
34. Reece TB, Davis JD, Okonkwo DO, Maxey TS, Ellman PI, et al. (2004) Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma. J Surg Res 121: 130-134.
35. Milne GR, Palmer TM, (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 11: 320-339.
36. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, et al. (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 1824: 68-88.
37. Reiser J, Adair B, Reinheckel T, (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120: 3421-3431.
38. Bird PI, Trapani JA, Villadangos JA, (2009) Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol 9: 871-882.
39. Colbert JD, Matthews SP, Kos J, Watts C, (2011) Internalization of exogenous cystatin F supresses cysteine proteases and induces the accumulation of single-chain cathepsin L by multiple mechanisms. J Biol Chem 286: 42082-42090.
40. Langerholc T, Zavasnik-Bergant V, Turk B, Turk V, Abrahamson M, et al. (2005) Inhibitory properties of cystatin F and its localization in U937 promonocyte cells. FEBS J 272: 1535-1545.
41. Magister S, Obermajer N, Mirkovic B, Svajger U, Renko M, et al. (2012) Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol 91: 391-401.
42. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, et al. (1999) Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur J Biochem 266: 1111-1117.